Format: Grand Rounds

1-4 of 4 Activities
Title
Availability
Format
Credits
Launch Date
Buttons
Live
Grand Rounds
1.00
09/12/2023 at 7:00 PM EST

Actionable Strategies in Community Oncology to Achieve Equity in Triple-Negative Breast Cancer

This Grand Rounds series focuses on educating, informing, and empowering clinicians involved in the care of patients with triple-negative breast cancer (TNBC) to positively impact the racial/ethnic disparities that negatively impact Black women. Our faculty will explore strategies that promote equitable care and outcomes for all patients; evaluate the role of antibody-drug conjugates (ADCs) in TNBC; and discuss the rapidly evolving clinical practice guidelines, safety and efficacy data of novel therapies, and practical ADC management strategies to anticipate and mitigate adverse events.

Join our expert faculty for this 60-minute program that will help you understand the complexity of TNBC and the far-reaching racial disparities intrinsic to the disease.

 

1.00
09/12/2023 at 7:00 PM EST

Rita Nanda, MD

Associate Professor of Medicine Director of Breast Oncology
University of Chicago
Chicago, Illinois

Rita Nanda, MD

Rita Nanda, MD, specializes in the treatment of all forms of breast cancer. Dr. Nanda’s practice focuses on women with triple-negative, hereditary, locally advanced and metastatic breast cancers. She is a strong advocate of using chemotherapy prior to surgery (neoadjuvant chemotherapy) to better understand how an individual’s tumor responds to therapy, so that treatment can be tailored to each patient’s unique case.

Live
Grand Rounds
1.00
09/21/2023 at 6:30 PM EST

Actionable Strategies in Community Oncology to Achieve Equity in Triple-Negative Breast Cancer

This Grand Rounds series focuses on educating, informing, and empowering clinicians involved in the care of patients with triple-negative breast cancer (TNBC) to positively impact the racial/ethnic disparities that negatively impact Black women. Our faculty will explore strategies that promote equitable care and outcomes for all patients; evaluate the role of antibody-drug conjugates (ADCs) in TNBC; and discuss the rapidly evolving clinical practice guidelines, safety and efficacy data of novel therapies, and practical ADC management strategies to anticipate and mitigate adverse events.

Join our expert faculty for this 60-minute program that will help you understand the complexity of TNBC and the far-reaching racial disparities intrinsic to the disease.

 

1.00
09/21/2023 at 6:30 PM EST

Sonya Reid, MD, MPH

Sonya Reid, MD, MPH

Hope S. Rugo MD

Professor, Division of Hematology/Oncology
Director, Breast Oncology Clinical Trials Education
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

Hope S. Rugo MD

Professor, Division of Hematology/Oncology
Director, Breast Oncology Clinical Trials Education
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

Hope S. Rugo MD

Professor, Division of Hematology/Oncology
Director, Breast Oncology Clinical Trials Education
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

Hope S. Rugo MD

Professor, Division of Hematology/Oncology
Director, Breast Oncology Clinical Trials Education
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA